Bluegrass Pharmaceuticals
Company

Bluegrass Pharmaceuticals

Biotechnology Research 2 employees
Employees
2

Bluegrass Pharmaceuticals Overview

Industry
Biotechnology Research
Employees
2
Founded
2024
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Bluegrass Pharmaceuticals

Research increasingly demonstrates that an over-active immune system and the resulting spikes in inflammation, are actually worse for healing. When injury first occurs, tissue specific macrophages initiate the inflammatory cascade by releasing cytokines into the blood stream. These inflammatory markers recruit additional macrophages to the site of injury. In chronic or deleterious forms of inflammation, these recruited macrophages arrive at the scene in M1 or “destructive” phenotype, long after necrotic tissue or pathogens are removed; causing unnecessary damage and perpetuating the cycle of inflammation. Our NF-kB blocker leverages a nano-particle delivery system to target and re-polarize recruited macrophages to the M2 or “restorative” phenotype, moderating inflammation and improving remodeling.

Bluegrass Pharmaceuticals Contact Details

People in AeroLeads
1

Bluegrass Pharmaceuticals Org Chart

Sample employees and titles
Name Title Contact
Ben Register Entrepreneur - Early Stage Biotech
View

Compare Similar Companies to Bluegrass Pharmaceuticals